---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-019765"
form_type: "8-K"
ticker: "RMD"
cik: "0000943819"
company_name: "RESMED INC"
filed_at: "2022-01-27T23:59:59+00:00"
generated_at: "2026-06-27T15:17:13.136757+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ResMed Q2 FY2022: Revenue $894.9M (+12% YoY), GAAP EPS $1.37, non-GAAP $1.47; dividend $0.42

## Summary
- Revenue $894.9M, up 12% YoY (13% constant currency); operating income $248.7M, up 12%.
- GAAP diluted EPS $1.37 (up 11%); non-GAAP diluted EPS $1.47 (up 4%).
- Gross margin contracted 140 bps GAAP to 56.4%; non-GAAP gross margin down 230 bps to 57.6%.
- Board declared quarterly cash dividend $0.42/share, payable March 17, 2022, record date Feb 10.
- CEO cited strong demand from competitor device recall, ongoing supply chain constraints.

## SEC filing metadata
- accession: 0001193125-22-019765
- form_type: 8-K
- ticker: RMD
- cik: 0000943819
- company_name: RESMED INC
- filed_at: 2022-01-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/943819/000119312522019765/0001193125-22-019765-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/943819/000119312522019765/d477629d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-019765
- JSON: https://secwatch.observer/filing/0001193125-22-019765.json
- Plain text: https://secwatch.observer/filing/0001193125-22-019765.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.